Ken Griffin Reata Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$79.22 - $105.37 $2.19 Million - $2.91 Million
-27,600 Reduced 19.77%
112,000 $11.4 Million
Q1 2023

May 15, 2023
SELL
$30.85 - $93.17 $1.77 Million - $5.35 Million
-57,400 Reduced 29.14%
139,600 $12.7 Million
Q4 2022

Feb 14, 2023
BUY
$22.15 - $42.11 $617,985 - $1.17 Million
27,900 Added 16.5%
197,000 $7.48 Million
Q3 2022

Nov 14, 2022
BUY
$19.41 - $36.49 $2.05 Million - $3.86 Million
105,800 Added 167.14%
169,100 $4.25 Million

Others Institutions Holding RETA

# of Institutions
5
Shares Held
62.7K
Call Options Held
0
Put Options Held
0
View Full List

About REATA PHARMACEUTICALS INC

RETA Quotes by TradingView
  • Ticker RETA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,583,200
  • Description
  • Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...
More about RETA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email